DDIT3 and mantle cell lymphoma: BR was associated with improved CR rates (50% vs. 27%, p = 0.017) and 5-year PFS (39.7% vs. 14.2%, HR 0.40 [0.21–0.75], p = 0.0035) in MCL patients, when compared to R-CHOP or R-CVP9.